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Posture changes platelet inhibition time  
after ingestion of prasugrel
Jacob Antonsen1, Nina Bundgaard1, Lene Holmvang2, Thomas Engstrøm2 & Kasper Iversen3
The use of percutaneous coronary intervention (PCI) 
over fibrinolysis has been proven to reduce the mortal-
ity and morbidity for patients with acute myocardial in-
farction [1]. For PCI to have a positive effect on mortal-
ity, it needs to be conducted no longer than 90-120 
min. after the first medical contact [2].
Numerous studies have proven the importance of 
reducing pre- as well as post-procedural platelet reac-
tivity in patients undergoing PCI [3, 4]. Efforts have 
been put into finding a “cut-off” target value for point-
of-care (POC) assays of platelet reactivity used to 
evalu ate the risk of complications after PCI [5-7]. 
The oral thienopyridine, prasugrel, has been proven 
to be superior to clopidogrel in the treatment of pa-
tients with acute coronary syndrome due to a faster 
and more consistent platelet inhibition [8]. Prasugrel is 
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ABSTRACT
InTRoduCTIon: Several studies have suggested that 
supine posture during pill ingestion prolongs oesophageal 
transit time. Whether ingesting prasugrel in an upright 
position leads to reduced platelet reactivity during 
percutaneous coronary intervention remains unclear.
MeThodS: A total of 20 people were randomly assigned to 
ingest 60 mg of prasugrel in either the supine or upright 
position. Platelet reactivity was analysed using the point-of-
care assay VerifyNow. 
ReSulTS: In the upright position, the velocity of platelet 
inhibition was highest between 20 and 40 min. (Δ = 101.9 
P2Y12 reaction units (PRU)). In the supine position, the 
highest value was seen between 40 and 60 min. (Δ = 56.85 
PRU). Time to reach the cut-off for reducing peri- and post-
operative risk of thrombosis showed a mean difference of 8 
min. in favour of the upright group.
ConCluSIonS: A trend towards faster reduction of platelet 
reactivity was seen when ingesting prasugrel in the upright 
position compared with the supine position.
FundIng: This work was supported by Oda and Hans 
Svenningsens Foundation (grant number: BOF-10109). The 
foundation had no part in the collection, analysis or 
interpretation of data, or in the writing of the report or the 
decision to submit the work for publication. 
TRIAl RegISTRATIon: This trial was registered with 
clinicaltrials.gov (NCT01365741).
 
a prodrug that is metabolised to one active metabolite 
(R-138727) and numerous inactive metabolites by  
the hepatic cytochrome P450, isoenzymes CYP3A4, 
CYP2B6 and, to a lesser extent, CYP2C9 and CYP2C19. 
The active metabolite binds irreversibly to the platelet 
P2Y12 ADP receptor and inhibits platelet aggregation.
Previous studies have shown that the passage of 
tablets through the upper gastrointestinal tract is 
highly variable and dependent on multiple factors in-
cluding body posture at the time of ingestion [9-12].  
In one study [10], 58% of tablets swallowed in the su-
pine position stayed in the oesophagus for more than 5 
min. Posture may influence the pharmacokinetics of 
orally administered drugs by affecting the rate of gas-
tric emptying, intestinal motility, absorption, splanch-
nic-hepatic blood flow, renal elimination, plasma vol-
ume and metabolism [13].
The purpose of this study was to investigate the dif-
ference in degree and velocity of thrombocytic inhibi-
tion between two different postures at the time of in-
gestion of 60 mg prasugrel. 
MeThodS
A total of 20 non-smoking, healthy males with no previ-
ous medical history aged 20-30 years participated in 
this study. All participants gave their written informed 
consent, and the study protocol conforms to the ethical 
guidelines of the 1975 Declaration of Helsinki. The 
Danish National Committee on Biomedical Research 
Ethics and the Danish Data Protection Agency ap-
proved the study (identification number H-15011038). 
Blood sampling: Before each experiment, a 1.7 mm 
(16 gauge) plastic indwelling catheter was inserted 
into the v. mediana cubiti and connected to a three-way 
stopcock and a shielded blood-collecting needle via a 
10-cc plastic tube. 
At 20-min. intervals after ingestion of 60 mg of 
prasugrel, 2 ml of blood was drawn for VerifyNow anal-
ysis using a citrate Vacuette. Before sampling for analy-
sis, 4 ml of blood were drawn on a K3 ethylenediamine-
tetraacetic acid (EDTA) tube, and after sampling the 
system was flushed with 0.9% saline.
Ingestion: A randomised cross-over trial with two 
phases and a two-week washout period was conducted. 
Participants were randomised at their first visit to ei-
ther the supine or the upright position, and thus the re-
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verse position at their next visit. Participants random-
ised to the supine position were laying on a hospital 
bed with no head elevation. They were instructed to 
swallow 6 × 10 mg of prasugrel with the use of 50 ml 
of water, through a straw. Thereafter, they were in-
structed to lie as still as possible for the duration of the 
experiment.
The participants who were randomised to the up-
right position followed the same instructions, but in-
gested the pills sitting in an upright position. They 
maintained the upright position for 120 sec. and were 
then invited to lie down. 
Platelet function testing: The antiplatelet activity of 
prasugrel was tested with turbidimetric optical detec-
tion (VerifyNow P2Y12 test; Accumetrics, San Diego, 
CA, USA) in citrate- anticoagulated whole-blood sam-
ples collected every 20 min. up to 100 min. The ADP-
activated platelets aggregated in the test channel on fi-
brinogen-coated microbeads, and the resultant change 
in optical signal was measured and expressed as P2Y12 
reaction units (PRU). In the control channel, platelets 
were activated with thrombin receptor-activating pep-
tides, and the baseline maximal aggregation was meas-
ured. 
Statistical analysis: The data were analysed using 
SPSS 20 software (SPSS Inc., Chicago, IL, USA). Re-
peated ANOVA measures were performed based on the 
difference calculated between the results for degree 
and velocity of thrombocytic inhibition in the supine 
and the upright position. The Wilcoxon signed rank test 
was used for calculation of differences in time to reach 
cut-off for PRU. A cut-off value for avoiding complica-
tions was set to ≤ 240 PRU. A p-value of < 0.05 was 
considered significant.
We also looked for the velocity of inhibition, being 
the delta values between two measurements (i.e. ∆T0-
T20, ∆T20-T40 etc.) to see how change in posture 
could affect the time to maximum velocity. The delta 
values were calculated, and the results from the supine 
group were subtracted from the results from the up-
right group. 
Power calculation: We expected a difference in time 
to inhibition of 15 min., a standard deviation of 10 min., 
risk of type 1 error of 0.05 and risk of type 2 error of 0.1. 
This yielded a sample size of seven. To reduce the risk of 
type 2 error, we chose to investigate 20 subjects. 
Trial registration: This trial has been registered with 
clinicaltrials.gov (NCT01365741).
ReSulTS
The baseline characteristics and values of the test 
group showed similarity (Table 1). The mean PRU 
value at baseline (T0) was 286 in the supine position 
and 272 in the upright position, (p = 0.6 for differ-
ence). The inhibition of thrombocyte function for the 
upright and the supine position appears from Figure 1 
and Figure 2. There was a statistically significant in-
crease in inhibition of the ADP receptor in both the su-
pine and the upright group from T = 40 to T = 100, 
when compared to T = 0 (p = 0.03 at T = 40 and p = 
0.000 at T = 60/80/100). 
When comparing the two groups, supine and up-
right, we saw a non-significant difference in baseline 
values of 15 PRU (standard error of mean = 26; p = 
0.6). Since we were interested in the difference be-
tween the supine and the upright position, we adjusted 
for this difference. Thus, we found a significant differ-
ence between the supine and the upright group at T = 
40 min. (p = 0.050) but a non-significant difference  
at T = 60 min. and T = 80 min. (p = 0.052, and p = 
0.066, respectively) (Table 2). 
Our analysis of the difference in velocity of throm-
bocytic inhibition between the two postures showed 
the largest difference at T40-T20 (48 PRU) and a spike 
at T100-T80 (10 PRU). This means that the maximum 
effect of posture change was seen at 20-40 min. after 
ingestion. When looking at each group in isolation, the 
biggest change in PRU values was seen in the 40-60-
min. range in the supine group (∆56.85 PRU) and in 
the 20-40-min. range in the upright group (∆101.9 
PRU).
TABle 1
Baseline characteristics (n = 20).
Gender: male, % 100
Age, mean (range), yrs 23 (20-29)
Weight, mean (range), kg 74.7 (68-90)
Height, mean (range), cm 179.5 (176-190)
BMI, mean (range), kg/m2 22.8 (20.7-24.9)
Ethnicity, %
Caucasian of Danish descent 90
Danish of Persian descent 10
TABle 2
The difference between supine and upright position after adjust-
ing for baseline differences. 
time, min. Difference in PRU, mean ± SEM (95% CI) p-value
T0  65.76 ± 26.10 (–65.76-36.36) 0.570
T20  53.91 ± 26.05 (–53.91-48.21) 0.913
T40 102.11 ± 26.05 (–102.11-0.14) 0.050
T60 101.76 ± 26.05 (–101.76-0.36) 0.052
T80  98.91 ± 26.05 (–98.91-3.21) 0.066
T100  88.66 ± 26.05 (–88.66-13.46) 0.149
CI = confidence interval; PRU = P2Y12 reaction units; SEM = standard error 
of the mean.
Dan Med J 65/10  October 2018 3
DANISH MEDICAL JOURNAL
Comparing the mean PRU values between the two 
groups, it was seen that at T = 40 min., the PRU values 
in both groups were below the cut-off of 240 (229 PRU 
in the supine group versus 178 in the upright group). 
The mean time to reach the PRU cut-off of ≤ 240 
was 40 min. in the upright position and 48 min. in the 
supine position. The difference, however, did not reach 
statistical significance (p > 0.05). 
dISCuSSIon
Our data showed a statistically significant difference in 
the time to inhibition of thrombocytic ADP receptors 
when comparing ingestion in the upright and the su-
pine position. We also observed a non-significant trend 
towards a faster likelihood of reaching the cut-off be-
fore interventional procedures. It has been shown that 
pre- and post-procedural platelet reactivity measured 
by VerifyNow has a prognostic significance for the de-
velopment of procedural complications [5, 14-16]. The 
consensus reached concerning the VerifyNow machine 
is that a pre- and post PRU of ≥ 240 increases the risk 
of post- and perioperative complications [5, 6, 8, 14, 
17]. Sibbing et al investigated thrombocytic inhibition 
using a somewhat similar POC assay (Multiplate, Roche 
Diagnostics Limited) to define a cut-off for procedural 
complications. They: “did not observe a gradual in-
crease of events across quintiles but a significant accu-
mulation of stent thrombosis in patients belonging to 
the upper quintile of MEA (Multiple Electrode Aggre-
gometry) measurements” [15], underlining the import-
ance of proper thrombocytic inhibition prior to PCI. 
VerifyNow was chosen because of its rapid results, 
easy handling and proven prognostic value in the 
evalu ation of PCI patients [5, 6, 14, 16, 17]. VerifyNow 
has a good correlation to light transmission aggregom-
etry (LTA) and vasodilator-stimulated phosphoprotein 
phosphorylation. It is shown to be reliable in the evalu-
ation of platelet inhibition [18, 19], even in the upper 
and lower quartiles of inhibition.
One of the potential strengths of this study is the 
use of prasugrel instead of clopidogrel as the drug of 
choice. Prasugrel has a more consistent pharmaco-
dynamics profile with improved efficacy and less 
inter individual variability. Studies have shown a non-
responder rate using clopidogrel in the 0-52% range, 
but only about 3% have been reported to be non-re-
sponders to prasugrel [20]. In our study, 15% of sam-
ples (three measurements in the upright group and 
three measurements in the supine group) did not 
reach the cut-off during the 100 min. Had the sam-
pling con tinued, the test subject might have had 
shown sensitivity to the drug later, but with regards to 
this study, they were “non-responders”, thus weaken-
ing our result. Cur rently, a newer platelet inhibitor, 
ticagrelor (Bril ique), has been introduced to the 
Danish market, but at the time of protocol approval, 
prasugrel was the preferred agent and, as described 
above, it showed potential strengths compared with 
clopidogrel and was thus our drug of choice for this 
randomised study.  
The weakness of this study is first and foremost the 
small sample size. Using a cross-over study has poten-
tially limited the effect of this weakness and increased 
the study’s statistical strength. Prasugrel is a pro-drug 
needing gastric absorption and hepatic metabolism to 
become activated, but our subjects did not fast before 
the experiment, which might have influenced our re-
sults. Our test subjects were all young, healthy males. 
FIguRe 2
Mean difference in P2Y12 reaction units (PRU) between supine and upright with standard  
error of the mean.
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Therefore, the results cannot be directly transferred to 
patients with acute cardiac ischaemia.  
Seeing that prasugrel is prone to give PRU values in 
the upper quartiles of inhibition, one might suspect 
that the VerifyNow would be less reliable due to its nar-
row dynamic range. Studies have been conducted 
showing a good correlation between LTA and Verify-
Now using prasugrel [19], even in the upper and lower 
quartiles of inhibition. This could possibly constitute a 
confounder in our study when looking at the overall 
difference between the supine and the upright position. 
Nevertheless, when looking at the velocity of inhibition 
in the mid quartiles of inhibition, this should have no 
effect on our results. 
ConCluSIonS
Our study showed a non-significant trend towards a 
faster reduction of platelet reactivity when ingesting 
prasugrel in the upright position than in the supine po-
sition. Larger clinical trials would be needed to confirm 
and assess the impact of posture on pharmacokinetics 
and its variability.
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